Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness AnalysisEdward Li, Gary H. Lyman, Dylan Mezzio et al.|JCO Oncology Practice|2021Cited by 19